Randomized in a 1:1 ratio, participants were treated with a maximum tolerated dose of tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg). The cohort included adults with obesity ...

Higher doses of tirzepatide were particularly effective, with mean fasting insulin percent reductions of 27.76% (P =.003; 10 mg dose) and 37.0% (P <.00001; 15 mg dose) compared with placebo. All doses ...

Mounjaro (tirzepatide) is a prescription drug that ... The strengths in this chart are given in milligrams per milliliter of solution (mg/mL). Mounjaro comes as a liquid solution in a prefilled ...

The 72‑week treatment period included a dose-escalation phase. Tirzepatide was started at a dose of 2.5 mg once weekly (or matching placebo) and the dose was increased by 2.5 mg every 4 weeks until ...

This approval was based on results from the SURMOUNT-OSA phase 3 clinical trials, which evaluated Tirzepatide (10 mg or 15 mg) for the treatment of moderate-to-severe OSA in adults with obesity, with ...

Currently, no treatments are available specifically for obesity-related HFpEF in the U.S. The multi-center trial used maximum tolerated dose of tirzepatide 5 mg, 10 mg or 15 mg once weekly.